Home > Notice & News   
 
.    24 1/2
Subject
Hyundai Pharm, Tranexamic Acid Topical Form Patent Application Completed
Content

(2015-10-14) On 14th, Hyundai Pharm announces that they submitted foreign patent application for HTB-003 (TA topical), world¡¯s first topical technology, on September 28th in 10 countries (U.S.A, Canada, Brazil, Mexico, Japan, china, India, Indonesia, Thailand, Vietnam). HTB-003 (TA topical) is a new topical chemical form indicated for melasma and freckles, and it is the world¡¯s first topical tranexamic acid product with changes in its use and form.

Tranexamic acid, a plasmin inhibitor, is known to be effective in freckles treatment which inhibits growth of melanin formative cell, melanin pigment, or arachidonic acid. Also, HTB-003 (TA topical) uses Hyundai¡¯s Transdermal Accelerating Technology which enables tranexamic acid to rapidly delivered into skin and sustain for a period of time. Not only that, it is known that

HTB-003(TA topical), as whitening management concept, is recognized with its value in improvement from cosmetics to a pharmaceutical grade product with its safety and efficacy much improved; it is expected its market to be much increased due to its uniqueness in dual use in monotherapy and surgery

Yeong Hak Kim, president of Hyundai Pharm, states that ¡°With patent application submission, I believe it was a good opportunity for HTB-003 (TA topical) to be recognized, the world¡¯s first topical formulation technology, value and its excellence. We plan to further improve this technology to develop much effective and safe freckles treatment.¡±

Date
2015-10-14
   
 
No.
Subject
Date
27
2015-11-09
2015-10-14
24
2015-09-02
23
2015-06-25
22
2015-05-12
21
2015-04-17
20
2015-03-26
19
2014-12-12
18
2014-12-05
17
2014-11-13
16
2014-08-19
15
2014-06-30
14
2014-06-05
13
2014-03-28
12
2014-02-18
     
 
main_footer